# Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

> **NCT05874635** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Signos Inc** · enrollment: 20000 (estimated)

## Conditions studied

- Weight Loss
- Metabolic Syndrome
- Diabetes Mellitus, Type 2
- Central Obesity
- Insulin Resistance
- Glucose Intolerance
- Metabolic Glucose Disorders

## Interventions

- **DEVICE:** Continuous Glucose Monitor Device

## Key facts

- **NCT ID:** NCT05874635
- **Lead sponsor:** Signos Inc
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-11
- **Primary completion:** 2028-05-10
- **Final completion:** 2029-05-10
- **Target enrollment:** 20000 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874635, "Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05874635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*